Walter M. Stadler, MD University of Chicago, discusses Biomarker Data From Phase II Randomized Trial Study of Atezolizumab With or Without Bevacizumab v Sunitinib at Kidney Cancer Association 2017 in Miami.
Biomarker Data From Phase II Randomized Trial Study of Atezolizumab With or Without Bevacizumab v Sunitinib
